- External Mentor
- Internal Mentor
President & CEO
After receiving Ph.D. of physical chemistry and molecular biology from University of Tokyo, he joined Kyowa Hakko Kogyo Co., in 1981. He contributed many positions there such as a member of the establishment of a molecular biology laboratory, where he was engaged in the development of full length cDNA cloning. In 1998, he established ReqMed Co., Ltd. and has been investing in domestic and overseas bio-ventures, fostering entrepreneurs, developing and marketing pharmaceuticals, and is currently working on the development of a treatment for pediatric rare-diseases. In 1992, he also received his MBA from Tsukuba University's evening graduate school for business person and in the summer of 1997, he completed “Executive Program in Strategic and Organization” at Stanford University's Graduate School of Business.
A graduate of Jichi Medical University, he began his research career at the Department of Cardiology, Stanford University in 2001, where he was involved in research and development, animal testing, and clinical trials for a U.S. medical device venture. He has extensive advisory experience in the medical device field and is familiar with the medical situation in Japan and the United States. He has also participated in projects involving Japanese and U.S. regulatory authorities in medical devices, and is working to establish a cross-border medical device ecosystem. In addition to his research, he has been teaching at Stanford University since 2014 as a member of the Stanford Biodesign Advisory Faculty, where he is training entrepreneurs in the medical device field. He is also deeply involved in the establishment of the Japanese version of Biodesign. He is actively working to establish a Silicon Valley-style medical device ecosystem in Japan.
He has nearly 30 years of experience in venture investment and drug discovery research.
He has been involved in the modern drug discovery at Research Centre Kyoto in Bayer and has been involved in drug discovery research in a wide range of fields including respiratory diseases. At Mitsui & Co. Global Investment, Inc. (MGI), he was responsible for investing to biotech and life sciences sectors and supported portfolio companies as board director or observer, contributing to an IRR of 40%+ over the past 16 years. He is also a member of the board of directors of Koinobori, a non-profit organization working with patients and their families to develop therapeutics for mitochondrial diseases. He received his M.Sc. in Medical Science from Osaka University Graduate School of Medicine. He is Professional engineer (bioengineering).
Director INDEE Singapore
Director Kubota Pharmaceutical Holdings
Tsuda is the co-founder of INDEE Japan, an innovation firm based in Tokyo. At INDEE Japan, he coaches corporates and startups to build new business models and develop them. His entrepreneurial skills are built from his intensive engineering experience and the diversity of projects.
Tsuda has various experiences in R&D of hard disk drives. For example, Tsuda was the engineering manager for the world’s smallest disk drive (Microdrive). He holds 17 patents in multiple disciplines; mechanical, electrical and software. Also, he has worked in engineering sites located in 8 countries as an indication of his talent in running a globally diverse team.
After an engineering career, he pursued a consulting business for R&D and innovation and later co-founded INDEE Japan. At INDEE Japan, he consults corporates grow and innovate and invests and coaches startups. He was also one of the founding team at INDEE Medical. INDEE Medical grew its regenerative medicine business and was successfully sold to M3. Tsuda also co-founded MENOU a visual inspection AI startup.
After working at a major commercial bank, he entered the venture capital industry after working at an investment bank, and for the last 20 years he has been engaged in investment and management support activities mainly in the biotechnology and medical startups. During this time, he has had the rare opportunity to be engaged in the startup companies from both the investor‘s and the venture company’s perspectives. Currently, he is providing various advisory support to startups based on his understanding of the thoughts of the academia that provides the seeds, the hearts of the entrepreneurs and managers who commercialize the seeds, and the minds of the investors who invest in the venture businesses.
After graduating from the Faculty of Engineering Science, Osaka University, he was engaged in product planning, development and marketing of catheters and artificial organs at Terumo Corporation. Served as General Manager of Development Planning Dept. at R&D Center, President of Catheter Company in Japan, and Deputy Plant Manager.
He was also transferred to the Innovation Promotion Center of the Yamaguchi Prefectural Industrial Technology Center for five years from 2014, where he contributed to the promotion of medical-related industries in the prefecture as a medical project producer.
After retiring, he used his experience and knowledge to support the development of many medical devices as a consultant.
He obtained his Ph. D. degree in the field of Medicine in University of Tsukuba in 2006, and worked for five years at Japan Science and Technology Agency (JST) to provide funding for basic researches. As one of the leading patent attorneys in Japan specializing in both prosecution and litigation, he has supported many prosecutions and developed new case law for new biotechnological technologies, and has proposed and provided practical support to academia and start-ups for patent strategies. As a result of these experiences, he has been serving as the chairman of the Bio-Life Science Committee of Japan Patent Attorneys Association (JPAA). In addition, in order to disseminate his knowledge and strategies throughout Japan, he has written columns for "Patent Attorney Morita's Patent “Offence and Defense" Strategy" on Nikkei Biotech Online since April 2017. He has also been involved in IP Acceleration program for Startups (IPAS) as an IP mentor since 2018.
Asia Pacific Innovation Center
Director, New Ventures Japan
He has worked as a drug discovery researcher for a total of 23 years in research laboratories of domestic and foreign pharmaceutical companies. During this time, he led several projects as a drug discovery researcher in the field of lifestyle-related diseases, where he created development candidates and led them through preclinical and clinical trials. After 3 years in Medical Affairs, he was in charge of academic support for diabetes drugs, including new drug launches, and data building through collaborations with academia, and was appointed to his current position in August 2014. As a scientific scout, he is in charge of nurturing seeds through evaluation and mentoring of early stage R&D projects in academia, startups and companies. He has signed many contracts (joint research, strategic partnerships, and research tool licenses).
・Worked in the research laboratory of a pharmaceutical company to create new drug candidates with novel target molecules/mechanisms for psychiatric/neurological diseases and severe infectious diseases with significant unmet medical needs.
・After that, in the consulting division of a think-tank, has been engaged in supporting new businesses and open innovation in the life science and healthcare fields for large corporations in many industries, including pharmaceuticals, medical devices, clinical testing, chemistry, heavy electric machinery, electronics, optical equipment, copiers, and system integration, utilizing their own/external technologies.
・Since 2017, has been involved in support for the foundation, growth, and open innovation of startups in the fields of Deep Tech, life science, and healthcare, as well as support for startup/innovation policies.
・Holds a graduate degree from Waseda University.
Executive Officer, General Manager of Life Science Dept.
In 1994, he joined Daiichi Pharmaceutical Co. (currently Daiichi Sankyo Company, Limited) , where he was assigned to the post-marketing surveillance division in charge of infectious diseases and oncology. He joined UFJ Capital Co., Ltd. (currently Mitsubishi UFJ Capital Co., Ltd.)in 2004. Since 2013, the company has been conducting an open innovation business based on research results from academia using OiDE Fund in collaboration with Daiichi Sankyo. In 2017, 2019 and 2020, Mitsubishi UFJ Life Science Fund No.1 (10 billion yen), No.2 (10 billion yen) and No.3 (10 billion yen) were established respectively to promote investment activities. He is currently an external director of Kamui Pharma, Chordia Therapeutics, Veritas In Silico, Gaia Biomedicine and Luxonus, and a fellow of the Industry-Academia Collaboration Promotion Organization, Graduate School of Medicine, Kyoto University.
After graduating from university, he worked in business development, product strategy, international business, and corporate strategy at Mitsubishi Tanabe Pharma Corporation, where he was involved in product licensing, alliance management, overseas business, and M&A. He established a corporate VC arm in Boston and invested in biotech startups in Europe and the US. After returning to Japan, he joined a healthcare company, where he launched regenerative medicine business (via startup investment and acquisition) and digital health business (via collaborations with startups and academia), and sold an active pharmaceutical ingredient (API) and intermediate manufacturing plant. In 2018, he launched TNAX Biopharma, University of Tsukuba spinoff, focusing on research and development of therapeutic antibodies for inflammatory and autoimmune diseases. Graduated from Kyoto University, Faculty of Pharmaceutical Sciences and MIT Sloan School of Management. He is a pharmacist.
Founder & Chief Executive Officer
Founder and CEO of the Japanese Organization for Medical Device Development, Inc. (JOMDD), the first incubator for medical devices and healthcare in Japan. He is a specialist for cardiology and internal medicine in Japan. He graduated the Harvard School of Public Health with a master degree in Epidemiology and completed the General Management Program at Harvard Business School. He is the first Japanese medical officer/reviewer at the U.S. Food and Drug Administration, Center for Devices and Radiological Health.
After succeed as a Medical Director at Boston Scientific Corporation, Taka worked as a consultant to support multiple medtech startups in the Bay area of U.S.A.
He also holds several academic roles, for example, committee member/review board/advisory for the Ministry of Health, Labour, and Welfare, Japan Agency for Medical Research and Development, etc.
Since joining Abbott Japan in 2000, he has been engaged in research and development of in vitro diagnostics for 15 years and has extensive experience in drug development for cancer and hepatitis. Since 2013, he has been engaged in the management of clinical research, regulatory submissions, and other late stage development activities.
He joined Shinsei Corporate Investment in 2016 and has been involved in investment execution and hands-on support for drug discovery and medical device startups. In February 2019, he was appointed as a partner of Shinsei Capital Partners, which manages the New Life Science 1 fund specializing in life sciences (current position). He is also an outside director of Veritas In Silico Co. He holds a Master's degree from Tokyo Institute of Technology.
Senior Director, Business Development
Graduated from the Faculty of Science, Kyoto University. D. in Life Science from Kyoto University. He had engaged in basic research on neurodegenerative disorders as a JSPS Research Fellow (DC2).
After Kyoto university, he joined a consulting firm “Dream incubator” and was in charge of industry-academia collaboration, investment in technology start-ups, new business development for large corporations, and new industry producing with Japanese government.
Previously, he worked for Abbott in Japan and Singapore. He was in charge of product marketing for diagnostics and pharmaceuticals in Japan, and area marketing for medical IT solutions in Asia Pacific. He was the only Japanese selected for the company‘s Asia Management Development Program, which selected 15 people in Asia. From 2019, he is working for a medical device incubator “JOMDD” and is leading a new medical device project for scoliosis and also invests medical device startups.
Hitotsubashi ICS, Adjunct Professor
He holds a B.A. in Law from the University of Tokyo and an M.B.A. from MIT.
He is currently preparing for the opening of Japan's largest urban startup campus (CIC Tokyo) in 2020.
He has 25 years of experience supporting companies at A.T. Kearney's Japan and U.S. offices. He specializes in strategy, innovation, and organization. He has served as A.T. Kearney's Japan Representative, Head Office Director, and Global Leader of the Consumer Goods and Retail Practice.
He has served on government committees on topics such as intellectual property strategy, Cool Japan, and inbound tourism. "He is the leader of the NEXTOKYO Project, which proposes a vision for the future of Tokyo and a special zone concept to industry and the government. He is the co-author of "NEXTOKYO" (Nikkei Business Publications, Inc.) and other books.
Chief Executive Officer
As the head of OMRON's Corporate Venture Capital (CVC), she has invested in ventures in Japan, Silicon Valley, Israel, and Europe. She is also involved in various activities in academia with the aim of developing an innovation ecosystem in the medical field. Prior to her current position, she was involved in the establishment of a medical device venture capital firm under the Innovation Network Corporation of Japan, where she invested in seed and early stage medical device ventures in Japan and Silicon Valley.
B.A. in Economics, Hitotsubashi University; M.B.A., Wharton School, University of Pennsylvania; Ph.D. (Biomedical Science), Joint Graduate School of Advanced Biomedical Sciences, Tokyo Women's Medical University, Waseda University; Faculty Fellow, Biodesign Program, Stanford University
After working for a pharmaceutical company and a medical device company in the U.S., she worked for a medical device company in Japan. Active as a global development executive. Board Member. Current position from 2019.
She is also a project researcher at the Economic Research Institute, Japan Society for the Promotion of Machine Industry, and a senior researcher at the Medical Device Industry Research Institute, Medical Device Center.
She has also served as an expert member of the Central Council of Medical Practitioners, a member of the PMDA relief operations committee, and vice chairman of the Growth Frontier Development Committee of Keizai Doyukai (Japan Association of Corporate Executives).
He joined Taiho Pharmaceutical in 2003 and has been engaged in drug discovery research. Later, in the Strategic Research Planning department, he led the promotion of collaboration with universities and biotech companies to search for seeds, evaluation of the early-stage assets, and development of portfolio strategies. In 2015, he was transferred to Remiges Ventures (an independent VC firm), where he was in charge of venture investment based in Boston, USA. I In July 2019, he joined Taiho Innovations, a corporate venture capital firm of Taiho Pharmaceutical, where he started incubation, company creation and investment activities in the Japanese healthcare space. Ph.D. in Pharmaceutical Sciences from the Graduate School of Pharmaceutical Sciences, University of Shizuoka.
After completing his Ph.D. studies at Hokkaido University, he spent a total of 10 years as a researcher in academia at RIKEN, Harvard Medical School, and Mie University School of Medicine, where he was engaged in oncology research and basic research on skin diseases. Aiming to create an ecosystem that enables rapid implementation of scientific findings in society, he then moved to Bayer's Open Innovation Center as an alliance manager and led new drug discovery projects in collaboration with academia, startups, and industry partners. In 2019, he joined LEO Pharma to become Senior Director of LEO Science & Tech Hub, which pioneers in creating innovative solutions for skin diseases. In addition to his role at LEO Pharma, he is also a Life Science Cluster Champion at Venture Café Tokyo, Impact Partner at Fresco Capital, and BioLabs Japan Liaison. He holds a pharmacist license.
He joined Eisai Co., Ltd. in 1979 as a researcher and previously served as Deputy Chief Clinical Officer of Neurology Clinical Development of Eisai. He has over 40 years Pharma R&D experiences based in US, Europe and Japan having held multiple management positions at Eisai including global clinical development (President, Eisai Medical Research Inc.), R&D strategy and planning, pharmacovigilance, post-marketing surveillance. His experience covers multiple therapeutic areas such as neurology, immunology, oncology, gastrointestinal and cardiovascular. He currently serves as President of MAJES Consulting LLC, which he founded after his retirement from Eisai, and Special Advisor to Cerveau Technologies Inc. He is currently involved in the development of drugs and diagnostics in the field of neurology particularly neurodegenerative diseases such as Alzheimer’s Disease.
Jun Yamadera founded Eyes, JAPAN co. ltd. in 1995, the first IT startup from the University of Aizu, Fukushima. In the past 20 years, he has been working on various cutting edge projects such as exporting Fukushima rice via web in 1995, making world’s first virtual pottery system, making CG of historical archives of national treasure of Japanese castles, temples, traditional dances and medical motions using motion capture. He is a pioneer in Augmented Reality wearable technologies, Medical x IT and has been organizing world’s first medical security hackathon since 2012. His team won the championship in Developers Challenge 2013 Health 2.0 in Silicon Valley. He is the Health 2.0 Fukushima Chapter Leader and a TEDxKobe 2015 Speaker. He started a project called “FUKUSHIMA Wheel” in the aftermath of the terrible disaster caused by the earthquake and nuclear accident in Fukushima, JAPAN in March 11, 2011. More than 24 years experience in Cutting Edge Technologies such as AI, Blockchain and Cyber Security.
Daiichi Sankyo CO., Ltd.
In 1988, he joined Daiichi Pharmaceutical Co., Ltd. (now Daiichi Sankyo Co., Ltd. ) and worked in clinical development (cardiovascular field), NHI drug price listing of new drugs and medical economy related work, and was transferred to the Institute for Health Economics and Policy. From 2003, he was a secretary of the NHI (National Health Insurance) Drug Price Research Committee of the Federation of Pharmaceutical Manufacturers‘ Associations of JAPAN(FPMAJ), and from 2008 to 2010, as secretary general of the same committee, he contributed to the introduction of the price maintenance premium (PMP). In 2015, he became a member of the Pharmaceutical Industrial Policy Committee of the Japan Pharmaceutical Manufacturers Association (JPMA), and in 2021 he was appointed Chairman of the Policy and Strategic Management Subcommittee of the same committee, where he is promoting activities related to policy advocacy and industrial policy.
Dennis Abremski is the Executive Director of the Institute for the Global Entrepreneur (IGE), a collaboration between the Jacobs School of Engineering and the Rady School of Management at the University of California San Diego. As a startup founder, business advisor, and serial entrepreneur, he has experience in consumer products and enterprise companies, and developed Software as a Service (SAAS) offerings in the wireless and healthcare markets. Abremski has built a career by balancing his business and technology expertise, having held executive positions in technology, international sales, business development, and operations.
York, a life science industry veteran, brings experience from Allergan, Amgen, Bristol-Myers Squibb, and Warner-Lambert. As an entrepreneur, he has started three companies. His most current is Akita Biomedical, a strategy, education, and medical communications firm since 2002. It has worked with a diversity of companies, ranging from startups to large multi-nationals. His startup portfolio includes MDEyeCare (Santiago, Chile), Omeza LLC. (Sarasota, FL), Startup Bridge (San Francisco, CA), and Vitreo Pharmaceuticals (Toronto, Canada). In the academic space, York has taught entrepreneurship, marketing, communication skills at the California Polytechnic State University and is currently at the University of California, San Diego where he lectures at the Institute for the Global Entrepreneur. He has spoken and coached in Japan, India, and the United Kingdom, and authored over twenty peer-review articles. He currently is pursuing a doctorate in business administration, with an emphasis in entrepreneurship at the Cranfield School of Management.
Jean-Jacques is currently working with BioLabs in Cambridge, Massachusetts, responsible for its international strategy. BioLabs creates innovation communities for biotechnology companies around shared fully equipped laboratories, helping start-up companies grow quickly and bridge the “valley of death”. The leading provider of ready-to-use wet lab spaces in the United States, BioLabs is now expanding internationally.
A Chemical Engineer by training, Jean-Jacques has worked over 15 years in the pharmaceutical and biotechnology industry in France (Transgene, Hybrigenics), in America and in Japan (Amgen, Sterling Winthrop, Rhône Poulenc).
With BpiFrance for nearly ten years (and its predecessor agencies Oseo and AII), Jean-Jacques was responsible for international partnerships and the Industrial Strategic Innovation program. In this capacity he worked with hundreds of technology companies to help their development, in France and internationally. The ISI program allocated over 1.2 billion euros in support to collaborative innovation projects.
Jean-Jacques joined the French Ministry of Foreign Affairs in 2013, as Attaché for Science and Technology in Boston. In this position, he was an observer of innovation support in America and responsible for programs (NETVA, YEI, FAID …) helping innovative companies from both countries expand their business abroad.
He holds a Ph.D. in genetics from the University of Tokyo.
After graduating from the Faculty of Pharmaceutical Sciences at Hokkaido University in 1975, he joined Eisai Co., Ltd., and engaged in drug discovery research. From 1988 through 1998, based in the U.S. and U.K., he worked for the promotion of research collaboration with academia and bio-venture companies, the establishment of the research laboratories at University College London, as well as for the establishment of overseas sales subsidiaries and preparations for the launch of new drugs in the U.S. and Europe. After working as Director of Corporate R&D Planning and Strategy, he was appointed as Corporate Executive Officer and President of Eisai European headquarters, Europe Limited in 2005. Since returning to Japan in 2009, he has held various positions in quality assurance, PR and government/industry affairs, healthcare policy, and China business. Appointed Representative Executive Officer and Executive Vice President in 2013 and Member of the Board in 2017 (current). During this period, he served as Chairman of the International Committee of the Japan Pharmaceutical Manufacturers Association, Deputy Director of the Office of Medical Innovation, Cabinet Secretariat, and as an expert member of the Central Social Insurance Medical Council.
Director, Tsukuba Research Center for Future Medical Engineering
Resident of Dept. of Neurosurgery at University of Tsukuba Hospital.
Studied tissue engineering of CNS at Keio University and tumor immunology at RIKEN.
Studied DDS with Nanotech. at Dept. of Biomedical Engineering, Johns Hopkins Medicine and the National Institute of Advanced Industrial Science and Technology (AIST) in Japan.
PI of the HAL clinical trial for stroke at University of Tsukuba.
Professor, University of Tsukuba Hospital
Director, T-CReDO Consultation Office
Department of Gastroenterology, University of Tsukuba Hospital
He is involved in the medical treatment and clinical trials of cancer drug therapy for 160 gastrointestinal cancer patients annually as an oncologist at the University of Tsukuba Hospital. He is primary investigator of multicenter clinical study for immune-related adverse events of immune checkpoint inhibitors. He supports the planning clinical trials in various fields, and provides education and training through ethics seminars at T-CReDO.
He is also working on the development of new therapies targeting cancer stem cells (in collaboration with RIKEN), and understands the development scheme of oncolytic virus from the viewpoint of oncology and immunology (Short-term study at Ottawa Hospital Research Institute). He is developing a new toilet seat in collaboration with a company. He is planning a clinical trial to evaluate the immunomodulatory function of agricultural products with National Agriculture and Food Research Organization.
Tsukuba Clinical Research and Development Organization
He has been engaged in basic drug discovery research, non-clinical development and clinical development at a foreign pharmaceutical company for 17 years. During that time, he was involved in four approved drugs. In 2007, he moved to the position of Director of Research and Development at the CREIL Center, a clinical research support organization at the University of Tsukuba. He was appointed as Director of the Central Coordinating Unit of the Tsukuba Clinical Research and Development Organization (T-CReDO) in 2016 due to organizational integration. He leads the study management and operations organization for investigator-initiated clinical trials and multicenter clinical trials. At the graduate school, he is the head of the translational research and regulatory science curriculum, and is also involved in student education.
Creative Manager, Open Innovation Strategy Organization
Since April 2019, Sosuke started working for his current position from Senior director of bioimaging research in Astellas Pharma Inc. where he worked for 28 years. He has been in charge of drug discovery translational science and drug discovery pharmacology at the University of Tsukuba, where he is also a professor in the Department of Medicine and Medical Sciences (Collaborative Graduate School) and the Global Education Institute (Collaborative Graduate School). He has also served as a member of the Tsukuba Life Science Promotion Council, Artificial Intelligence Science Center Steering Committee, and JST ERATO Evaluation Committee. He is currently a visiting professor at the Department of Drug Discovery Science, United Graduate School of Drug Discovery and Medical Informatics, Gifu University, where he is in charge of the Pharmaceutical Bioindustry and the Drug Discovery Human Resource Development Education Program. Also, he studied at the University of Washington, Seattle from 2003 to 2005. His publications include Application of Imaging Technology in Drug Discovery Research and Introduction of Molecular Imaging Technology in Drug Development. Awards: HIRUMA/WAGNER Award /The 13th International Conference of Peace through Mind Brain Science, and many others.
After graduating from the Graduate School of the University of Tokyo, he joined the Ministry of Health and Welfare (now the Ministry of Health, Labour and Welfare) in 1985, where he was involved in various fields of administration as a technical administrative officer, focusing on pharmaceutical administration. In particular, he was in charge of new drug evaluation for many years, as well as the promotion of R&D of pharmaceuticals and medical devices, post-marketing safety measures, food sanitation, and waste management. As a senior official of the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA), he served as Director of the Pharmaceutical Evaluation Division, MHLW; Director of the Clinical Trial Promotion Office, MHLW; Chief Safety Officer, PMDA; Associate Center Director (New Drug Evaluation), Center for Product Evaluation, PMDA; and Office Director of the Office of New Drug I, PMDA, and he has been in his current position since 2021. He is in charge of R&D support and project management for pharmaceuticals and medical devices, utilizing his over 30 years of experience in regulatory system changes such as amendments to the Pharmaceutical Affairs Law and his knowledge of the pharmaceutical regulatory system in general, as well as his experience in the R&D process of pharmaceuticals and their evaluation.
After working as a Senior Research Fellow in the Pharmacology Research Laboratories at Astellas Pharma Ltd, he was engaged in translational research (TR) as a Translational Scientist in the Exploratory Development Division of Astellas Europe BV in Netherlands. After returning to Japan, he served as the Head of the Translational Science Research Labs, and as Executive Director of the Alliance Station & Professor of Alliance Laboratory for Advanced Medical Research, which is the company's industry-academia collaboration base at Kyoto University. With these expertise and experiences in TR & industry-academia collaboration, he has served in the current position since April 2020. He is engaged in strategies for commercialization of drug discovery research in academia.
He holds teaching positions at University of Tsukuba, Nihon University, Kyoto University and Okayama University to raise the next generations. Completed graduate school of Tokyo University of Science.
He has been engaged in basic development, product development, business planning, and global collaboration for analytical and in vitro diagnostic instruments at a major in vitro diagnostic instrument manufacturer. Since July 2015, she has been working at the University of Tsukuba, where she has been engaged in technology transfer, bridge promotion, and project management related to medical devices and regenerative medicine.
In 1983, he joined Mitsubishi Tanabe Pharma Corporation (formerly Mitsubishi Petrochemical Co., Ltd.). He engaged in drug discovery research in the fields of cardiovascular, diabetes, and nephrology at the Institute of Pharmacology. After extensive experience in project initiation, HTS, optimization studies, preclinical studies, and studies for regulatory submissions, he became the Pharmacology Group Leader in charge of the cardiovascular area and led drug discovery research. In 2011, he moved to the development department, where he was in charge of technical evaluation of in-licensed candidates, and in 2014, he became the global development team leader in charge of early-stage development products in immune inflammation and rare diseases. He has been in his current position since 2018. He is currently promoting the commercialization of seeds from academia by providing support based on his extensive practical experience from drug discovery research to development programs.
At a R&D-oriented company in the field of medical devices and materials, he engaged in all aspects of the product development process from product development to regulatory submission in a wide range of fields including diagnostics, combination products, medical devices, and regenerative medicine.
He has been in his current position since April 2020.
Based on his experience, he proposes product commercialization strategies including regulatory and institutional perspectives such as pharmaceutical affairs and insurance, and provides support to researchers who have promising seeds with an eye to their exit in the medical field.
Research and Development Manager, Department of Research and Development Management
Achieved the launch of a thrombopoietin receptor agonist, which was started from screening of low-molecular-weight compounds during Yamanouchi/Astellas Pharma. In addition, through drug repositioning, I found out-licensing candidates for drugs that had been discontinued in clinical trials. As a leader, I have led many collaborations with academia and government both in Japan and overseas. I have been in my current position since 2021. My goal is to bring health and happiness to people around the world by promoting medical seeds from academia, including Tsukuba University, toward clinical trials. I graduated Kyoto University.